Professor of Targeted Therapeutics and Chair of Cancer Phage Therapy.
Imperial College London, United Kingdom
Amin Hajitou completed his PhD at The University of Liège, Belgium and acquired extensive experience in gene delivery technologies. During his postdoctoral training at the MD-Anderson Cancer Center in Texas-USA, he gained expertise in phage-guided gene delivery and designed a hybrid phage vector that showed first success of systemic gene targeting of cancer. In 2008, Hajitou established his team as a Lecturer, at Imperial, and became Full Professor in 2019. Professor Amin Hajitou has become a globally recognised pioneer in the field of Cancer Phage Therapy, currently serving as Professor of Targeted Therapeutics and the Chair of Cancer Phage Therapy at Imperial College London. At Imperial, he developed novel and superior generations of hybrid phage delivery systems, a milestone that laid the foundation for a new therapeutic paradigm. His therapeutic platform has demonstrated successful treatment of various types of cancers in animals models, independent groups reported efficacy of intravenous cancer gene therapy in preclinical models, and the technology is now advancing towards first-in-human clinical trials in cancer patients.
Hajitou’s research leadership has been recognised through numerous awards, patents, high-profile publications, and global collaborations. He has also been decorated with a Royal Medal by His Majesty the King of Morocco and honoured by the Government of Thailand following international recognition of his students’ academic achievements. In addition to his academic contributions, Hajitou has played a role in industry through start-up ventures and collaborations with pharmaceutical companies.
